Penn Medicine
Help | Search | Site Map | Contact   
faculty photo

Pablo Tebas, MD

Professor of Medicine (Infectious Diseases) at the Hospital of the University of Pennsylvania
Attending Physician, Hospital of the University of Pennsylvania
Director & Principal Investigator, AIDS Clinical Trial Unit (ACTU) research site, University of Pennsylvania
Investigator of the Vaccine Trials Network, University of Pennsylvania
Department: Medicine

Contact information
Academic Address: 502 Johnson Pavilion
Clinical Office: 4 Perelman Center for Advanced Medicine, 3600 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215-349-8092
Fax: 215-349-8011
Education:
MD
Universidad Autónoma de Madrid, Spain, 1985.
Post-Graduate Training
Intern in Medicine, Hospital Puerta de Hierro, Madrid, Spain, 1986-1987.
Resident in Medicine, Hospital Puerta de Hierro, Madrid, Spain, 1987-1991.
Fellowship, Infectious Diseases, Washington University in Saint Louis, Missouri, 1992-1995.
Certifications
Spanish Board of Internal Medicine, 1992.
American Board of Internal Medicine, Internal Medicine, 2014.
American Board of Internal Medicine, Infectious Diseases, 2015.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

My research interests center around the study of the complications of HIV and its treatment, and currently in the evaluation of strategies for the cure of HIV infection.
I am the director and the PI of the AIDS clinical trial unit of the University of Pennsylvania.
I am one of the founding members of the HIV Reservoirs and Viral Eradication (Cure) Transformative Science Group (TSG) of the AIDS clinical trial group. In addition to my ACTG work, I am involved (as PI of the clinical project) in several early phase trials of new compounds developed in conjunction with the NIH in several IPCP grants, including a Phase I study evaluating the antiviral activity of aprepitant (an NK-1R antagonist that down-regulates the expression of CCR5), a phase I study evaluating the immunogenicity of a therapeutic DNA vaccine administered by intramuscular electroporation in collaboration with David Weiner and several gene therapy studies evaluating the therapeutic use of lentiviral vectors in the management of HIV infection (including the use of VIRxSYS 496 –antisense approach-, the first in humans Sangamo’s zinc finger nuclease for CCR5 edition, in collaboration with Dr. Carl June.

Description of Clinical Expertise

My clinical interest focus on the treatment of HIV infection and associated infections like hepatitis C. I have also a particular interest in the clinical manifestations and treatment of atypical mycobacterial infections. I also attend every year in the general infectious disease service of the hospital of University of Pennsylvania

Selected Publications

Board, N. L., Yuan, Z., Wu, F., Moskovljevic, M., Ravi, M., Sengupta, S., Mun, S. S., Simonetti, F. R., Lai, J., Tebas, P., Lynn, K., Hoh, R., Deeks, S. G., Siliciano, J. D., Montaner, L. J., Siliciano, R. F.: Bispecific antibodies promote natural killer cell-mediated elimination of HIV-1 reservoir cells. Nat Immunol January 2024.

Jacobson, J. M., Felber, B. K., Chen, H., Pavlakis, G. N., Mullins, J. I., de Rosa, S. C., Kuritzkes, D. R., Tomaras, G. D., Kinslow, J., Bao, Y., Olefsky, M., Rosati, M., Bear, J., Hannaman, D., Laird, G. M., Cyktor, J. C., Heath, S. L., Collier, A. C., Koletar, S. L., Taiwo, B. O., Tebas, P., Wohl, D. A., Belanzauran-Zamudio, P. F., McElrath, M. J., Landay, A. L., Actg Study Team: The immunogenicity of an HIV-1 gag conserved element DNA vaccine in people with HIV and receiving antiretroviral therapy. AIDS December 2023.

Bilger, A., Plenn, E., Barg, F. K., Rendle, K. A., Carter, W. B., Lamour-Harrington, A., Jones, N., Peterson, B., Sauceda, J. A., Tebas, P., Mounzer, K., Metzger, D., Montaner, L. J., Dube, K.: Participant experiences in HIV cure-directed trial with an extended analytical treatment interruption in Philadelphia, United States. HIV Res Clin Pract 24(1): 2267825, October 2023.

Anesi, G. L., Degnan, K., Dutcher, L., Saw, S., Maguire, C., Binkley, A., Patel, S., Athans, V., Barton, T. D., Binkley, S., Candeloro, C. L., Herman, D. J., Kasbekar, N., Kennedy, L., Millstein, J. H., Meyer, N. J., Talati, N. J., Patel, H., Pegues, D. A., Sayre, P. J., Tebas, P., Terico, A. T., Murphy, K. M., O'Donnell, J. A., White, M., Hamilton, K. W.: The Penn Medicine COVID-19 Therapeutics Committee-Reflections on a Model for Rapid Evidence Review and Dynamic Practice Recommendations During a Public Health Emergency. Open Forum Infect Dis 10(8): ofad428, August 2023.

McMyn, N. F., Varriale, J., Fray, E. J., Zitzmann, C., MacLeod, H. J., Lai, J., Singhal, A., Moskovljevic, M., Garcia, M. A., Lopez, B. M., Hariharan, V., Rhodehouse, K., Lynn, K., Tebas, P., Mounzer, K., Montaner, L. J., Benko, E., Kovacs, C., Hoh, R., Simonetti, F. R., Laird, G. M., Deeks, S. G., Ribeiro, R. M., Perelson, A. S., Siliciano, R., Siliciano, J. M.: The latent reservoir of inducible, infectious HIV-1 does not decrease despite decades of antiretroviral therapy. J Clin Invest July 2023.

Mamidi, R. S., Ayubcha, C., Rigney, G., Kirschner, J., Gerke, O., Werner, T. J., Tebas, P., Alavi, A., Revheim, M. E.: A prospective 18 F-fluorodeoxyglucose positron emission tomography/computed tomography study of the neurometabolic effects in cocaine use and HIV infection. AIDS 37(6): 905-912, May 2023.

Tebas, P., Lynn, K., Azzoni, L., Cocchella, G., Papasavvas, E., Fair, M., Karanam, B., Sharma, P., Reeves, J. D., Petropoulos, C. J., Lalley-Chareczko, L., Kostman, J. R., Short, W., Mounzer, K., Montaner, L. J.: Susceptibility to 3BNC117 and 10-1074 in ART suppressed chronically infected persons. AIDS April 2023.

Schnittman, S. R., Lu, M. T., Mayrhofer, T., Burdo, T. H., Fitch, K. V., McCallum, S., Fulda, E. S., Zanni, M. V., Foldyna, B., Malvestutto, C., Fichtenbaum, C. J., Aberg, J. A., Bloomfield, G. S., Overton, E. T., Currier, J., Tebas, P., Sha, B. E., Ribaudo, H. J., Flynn, J. M., Douglas, P. S., Erlandson, K. M., Grinspoon, S. K.: Cytomegalovirus Immunoglobulin G (IgG) Titer and Coronary Artery Disease in People With Human Immunodeficiency Virus (HIV). Clin Infect Dis 76(3): e613-e621, February 2023.

Hait, S.H. , Shrader, H. , Lovelace, S. , Coates, E. , Rothwell, R.S. , Donaghy, E. , Fichtenbaum, C.J. , Santana, J. , Presti, R. , Roa, J. , Bhatnagar, A. , Lynch, R.M. , Tebas, P. , Mascola, J.R. , Pegu, A.: Efficacy and Complementarity of HIV-1 Suppression by CD4-Binding bNAbs. 30th Conference on Retrovirus and Oppotunistic infections. February 19-22, 2022 Seattle, Abstract #307 February 2023.

Wu, V. H., Nordin, J. M. L., Nguyen, S., Joy, J., Mampe, F., Del Rio Estrada, P. M., Torres-Ruiz, F., Gonzalez-Navarro, M., Luna-Villalobos, Y. A., Avila-Rios, S., Reyes-Teran, G., Tebas, P., Montaner, L. J., Bar, K. J., Vella, L. A., Betts, M. R.: Profound phenotypic and epigenetic heterogeneity of the HIV-1-infected CD4(+) T cell reservoir. Nat Immunol 24(2): 359-370, Feb 2023.

back to top
Last updated: 02/15/2024
The Trustees of the University of Pennsylvania
 
© The Trustees of the University of Pennsylvania. Site best viewed with a supported browser.
SOM Home International Programs Penn Alumni Clinical Trials Centers and Institutes Departments Faculty Research Education Administration